Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2001

01-07-2001

Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study*

Authors: Pier Franco Conte, Alessandra Gennari, Sara Donati, Barbara Salvadori, Editta Baldini, Carmelo Bengala, Ilaria Pazzagli, Cinzia Orlandini, Romano Danesi, Stefano Fogli, Mario Del Tacca

Published in: Breast Cancer Research and Treatment | Issue 2/2001

Login to get access
Metadata
Title
Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study*
Authors
Pier Franco Conte
Alessandra Gennari
Sara Donati
Barbara Salvadori
Editta Baldini
Carmelo Bengala
Ilaria Pazzagli
Cinzia Orlandini
Romano Danesi
Stefano Fogli
Mario Del Tacca
Publication date
01-07-2001
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 2/2001
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1023/A:1011945623464

Other articles of this Issue 2/2001

Breast Cancer Research and Treatment 2/2001 Go to the issue

OriginalPaper

Rural-urban differences in radiation therapy for ductal carcinoma in-situ of the breast

OriginalPaper

Immunohistochemical analysis of prostate specific antigen in breast cancer*

OriginalPaper

Induction of apoptosis in mammary gland by a pure anti-estrogen ICI 182780

OriginalPaper

Biomarker prediction of clinical outcome in operable breast cancer patients treated with tamoxifen

Instructions for Authors

Instructions for authors

OriginalPaper

Premorbid body weight and its relations to primary tumour diameter in breast cancer patients; its dependence on estrogen and progesteron receptor status
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits